Altesa Biosciences develops drugs to treat RNA viruses, which are responsible for 80% of viral diseases worldwide. Among these viruses are Rhinovirus (primary cause of the common cold), Influenza, Respiratory Syncytial Virus (RSV), Dengue virus, Yellow Fever virus, Ebola virus and SARS-CoV-2 (COVID-19).
Altesa Biosciences website »
Altesa Biosciences website »
Location: United States
Total raised: $75M
Investors 1
| Date | Name | Website |
| - | GRA Ventur... | graventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.02.2026 | Series B | $75M | Forbion |
Mentions in press and media 8
| Date | Title | Description |
| 20.02.2026 | Altesa BioSciences Raises $75M Series B | ATLANTA, GA, Altesa BioSciences has announced a $75 million oversubscribed Series B funding round. >> Click here for more funding data on Altesa BioSciences >> To export Altesa BioSciences funding data to PDF and Excel, click h... |
| 19.02.2026 | Altesa BioSciences Raises $75M in Series B Funding | Altesa BioSciences, an Atlanta, GA-based clinical-stage pharmaceutical company raised $75M in Series B funding. The round was led by Forbion, with participation from Sanofi and existing investors, including Medicxi, Pitango, and Atlantic Pa... |
| 19.02.2026 | Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseases | - |
| 19.02.2026 | Sanofi backs Altesa's $75M series B to bankroll antiviral's midstage rhinovirus study | Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. Altesa BioSciences unveiled back in 2022 with $4 million in seed funding and a mission to build upon the work of t... |
| 10.05.2023 | NCPDP Announces Highlights from its 2023 Annual Conference, “The Great Race to Close Gaps in Care” | National Council for Prescription Drug Programs (NCPDP) SCOTTSDALE, Ariz. (PRWEB) May 10, 2023 NCPDP announced today highlights from its 2023 Annual Technology & Business Conference, The Great Race to Close Gaps in Care. The high energy... |
| 07.07.2021 | Vaxart : Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset | Milestone payments up to $130 million and royalties for global Vapendavir sales Vapendavir has demonstrated activity against a broad spectrum of enteroviruses SOUTH SAN FRANCISCO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasd... |
| - | Altesa | “Home - Altesa BioSciences” |
| - | Altesa | “Altesa BioSciences | Developing Treatments For Respiratory Viruses and Global Viral Threats” |